Pharmaceutical company Dr Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE: RDY) on Thursday announced the availability of its antipsychotic medication Fluphenazine Hydrochloride Tablets, USP in the US market.
Fluphenazine Hydrochloride Tablets, USP are a therapeutic equivalent generic version of Prolixin Tablets, 1 mg, 2.5 mg, 5 mg and 10 mg, and are approved by the US Food and Drug Administration (FDA).
The Prolixin brand and generic had US sales of approximately USD134m MAT for the 12 months ending in December 2020, according to IQVIA Health.
Fluphenazine is used in the treatment of chronic psychoses such as schizophrenia and psychotic symptoms such as hallucinations, delusions and hostility.
Abbisko Therapeutics reports US FDA acceptance of pimicotinib NDA
Formosa Pharmaceuticals licenses APP13007 ophthalmic therapy to Samil for South Korea
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Sanofi's Teizeild approved in EU to delay stage 3 type 1 diabetes
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
EQT Life Sciences exits Vivasure Medical in EUR185m sale to Haemonetics
FDA accepts NDA resubmission for Camurus' acromegaly drug Oclaiz
Saluda Medical secures CE certification for EVA Sensing Technology in Europe
Arbele's ARB1002 receives US FDA Orphan Drug Designation
Compass Pathways wins FDA IND acceptance for COMP360 PTSD trial